Filament Health Corp is a natural psychedelic drug development company. Its mission is to see safe, approved, natural psychedelics in the hands of everyone who needs them as soon as possible. The group engages in natural extraction technology commercialization, utilizing its intellectual property portfolio, in-house GMP facility, and Health Canada psilocybin Dealer's License.
Clinical Trials
2
2 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Not yet recruiting
2
100.0%
No approval data available
- Red Light Holland reported fiscal 2026 audited results and announced its corporate rebrand to Rhelion Life Sciences Corp., effective August 4, 2026, reflecting a shift toward a science-first psychedelic drug development organization. - The acquisition of Filament Health Corp. provides Rhelion with 76 issued patents across 13 patent families, GMP manufacturing infrastructure, and the botanical psilocybin drug candidate PEX010, which has completed Phase I clinical development. - PEX010 and additional naturally derived psychedelic candidates are Phase II-ready, with the company actively exploring advancement into a Phase 2b clinical program targeting serious mental health and substance use disorders. - The company reported total cash of $8.471 million, revenue of $4.195 million, and an adjusted EBITDA loss of $2.931 million for fiscal 2026, while continuing to divest non-core assets to focus capital on its pharmaceutical platform.
- Red Light Holland Corp. announced a definitive agreement to acquire Filament Health Corp. through an all-share transaction, combining complementary assets in natural psychedelic drug development. - The merger integrates Filament's 76 issued patents covering natural psilocybin manufacturing, GMP-compliant facility, and Health Canada Level 8 Controlled Substances Dealer's Licence with Red Light's operational scale and microdosing expertise. - Filament's lead botanical psilocybin drug candidate PEX010 currently supplies over 70 clinical research sites globally, while the combined company plans to advance Phase 2 trials for substance use disorders. - The transaction positions the merged entity to commercialize patented microdosing psilocybin drugs in jurisdictions with emerging regulatory pathways, with completion expected in Q2 2026.
